Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 4Biliary Tract Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Neuroendocrine Tumor Grade 3 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neuroendocrine Tumor Grade 3 × surufatinib × Clear all
NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Unknown
32 enrolled
EndocrineNET

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡